Latest News & Updates

FDA approves ruxolitinib for chronic graft-versus-host disease
September 23, 2021

Continue Reading »

FDA approves cabozantinib for differentiated thyroid cancer
September 22, 2021

Continue Reading »

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer
September 21, 2021

Continue Reading »

How the new DNA privacy law could affect your practice
September 20, 2021

Continue Reading »

FDA approves ruxolitinib for chronic graft-versus-host disease
September 23, 2021

Continue Reading »

FDA approves cabozantinib for differentiated thyroid cancer
September 22, 2021

Continue Reading »

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer
September 21, 2021

Continue Reading »

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
September 16, 2021

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: